Aliskiren/amlodipine/hydrochlorothiazide

Aliskiren/amlodipine/hydrochlorothiazide

Combination of
Aliskiren	Renin inhibitor
Amlodipine	Calcium channel blocker
Hydrochlorothiazide	Diuretic
Clinical data
Trade names	Amturnide
AHFS/Drugs.com	Micromedex Detailed Consumer Information
License data	US  DailyMed:  Amturnide
Routes of administration	By mouth
ATC code	C09XA54 ( WHO )
Legal status
Legal status	US: ℞-only [1]
Identifiers
PubChem CID	56841821
KEGG	D10291  Y
Chemical and physical data
Formula	C57H86Cl2N8O15S2
Molar mass	1258.38 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN.CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N.C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl
InChI InChI=1S/C30H53N3O6.C20H25ClN2O5.C7H8ClN3O4S2/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36;1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35);5-8,17,23H,4,9-11,22H2,1-3H3;1-2,10-11H,3H2,(H2,9,12,13)/t22-,23+,24-,25-;;/m0../s1 Key:YJDDFLDXUPNQTO-WMEHTASQSA-N
(verify)

Aliskiren/amlodipine/hydrochlorothiazide, sold under the brand name Amturnide, is a fixed-dose combination medication that is used to treat high blood pressure. ^{[1] [2]} It contains aliskiren, a renin inhibitor; amlodipine, as the besylate, a calcium channel blocker; and hydrochlorothiazide, a thiazide diuretic. ^[1] It is taken by mouth. ^[1]

It was approved for medical use in the United States in December 2010. ^{[1] [3] [4]} Amturnide was withdrawn by Novartis from the US market in 2017. ^[5]

References

1. "Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets, for oral use Initial U.S. Approval: 2010". DailyMed. 10 November 2016. Retrieved 6 February 2022.
2. Neutel JM, Smith DH (October 2013). "Hypertension management: rationale for triple therapy based on mechanisms of action". Cardiovascular Therapeutics. 31 (5): 251–8. doi:10.1111/1755-5922.12015. PMID   23121769.
3. "Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets, for oral use Initial U.S. Approval: 2010". DailyMed. Retrieved 5 July 2024.
4. "Drug Approval Package: Amturnide(amlodipine/aliskiren/hydrochlorothiazide) NDA #200045". U.S. Food and Drug Administration (FDA). 15 August 2011. Retrieved 27 August 2020.
   • Lay summary in: "Center for Drug Evaluation and Research: Application Number: 200045Orig1s000: Summary review" (PDF). Food and Drug Administration.
5. "Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications". Federal Register. 21 June 2017. Retrieved 6 February 2022.

External links

• "FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekturna)". U.S. Food and Drug Administration (FDA). 29 June 2021. Archived from the original on 23 September 2019.